Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal
Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.
Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.
What's Your Reaction?
